NEW YORK – Taconic Biosciences said Monday that it has entered into an exclusive license agreement with German biomedical research center Helmholtz Munich to provide preclinical researchers with CRISPR gene editing services.

纽约——塔科尼克生物科学公司周一表示，已与德国生物医学研究中心亥姆霍兹慕尼黑达成独家许可协议，将为临床前研究人员提供CRISPR基因编辑服务。

Under the agreement, the financial details of which were not disclosed, Taconic has acquired the exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich to improve the generation of genetically modified animal models for biomedical research.

根据这项未披露财务细节的协议，Taconic 已获得一项在亥姆霍兹慕尼黑中心开发的、基于 CRISPR 的基因编辑技术的独家专利权，以改进用于生物医学研究的转基因动物模型的生成。

'This technology significantly enhances

“这项技术显著增强了

Taconic's

塔科尼克的

ExpressModel

快速模型

platform to deliver high-quality, precise CRISPR-Cas9-generated custom animal models on an accelerated timeline to our customers,' Taconic Biosciences CEO Mike Garrett said in a statement.

Taconic Biosciences首席执行官迈克·加勒特在一份声明中表示：“这是一个平台，能够以加快的时间表向我们的客户交付高质量、精确的CRISPR-Cas9生成的定制动物模型。”

Wolfgang Wurst, co-inventor of the licensed technology at Helmholtz Munich, added in a statement that combining the institute's CRISPR technology with Taconic's expertise in animal model generation and breeding is expected 'to accelerate the creation of precise models that uncover the genetic basis of diseases — supporting scientific discovery and paving the way for future medical breakthroughs.'.

沃尔夫冈·伍斯特（Wolfgang Wurst）是亥姆霍兹慕尼黑中心授权技术的共同发明人，他在一份声明中补充道，将该研究所的CRISPR技术与Taconic在动物模型生成和繁殖方面的专业知识相结合，预计将“加速开发揭示疾病遗传基础的精确模型——推动科学发现，并为未来的医学突破铺平道路”。